IL1B and lung cancer: RES suppressed the inflammatory microenvironment, decrease the expressions of p‐NF‐ĸB, IL‐1β, IL‐8, and IL‐23, and inactivate the STAT3/VEGF signaling pathway, thereby reducing drug resistance in lung cancer cells.